Developing product label information to support evidence-informed use of vaccines in pregnancy.
CONCLUSIONS: The revised statements for IIV and Tdap aligned with workshop participants' goals that the product label be evidence-based, with a consistent structure and language that is easily understood by healthcare providers. Emergent methods uncovered stakeholder concerns about the regulatory purpose, content, and evidence used in product labels. Involving healthcare providers in the development and regular updating of product information could prevent interpretations of that information that contribute to vaccine hesitancy.
PMID: 31594709 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Manca TA, Graham JE, Dubé È, Kervin M, Castillo E, Crowcroft NS, Fell DB, Hadskis M, Mannerfeldt JM, Greyson D, MacDonald NE, Top KA, Canadian Vaccine Product Monograph Working Group Tags: Vaccine Source Type: research
More News: Allergy & Immunology | Canada Health | Clinical Trials | Diphtheria | Epidemiology | Influenza | Influenza Vaccine | International Medicine & Public Health | Medical Ethics | Pregnancy | Tetanus | Tetanus Diptheria Pertussis Vaccine Tdap,Dtap,Dpt | Tetanus Vaccine | Vaccines | Whooping Cough (Pertussis) Vaccine | Workshops